SENS - CONSENSUS CO - Senseonics Holdings

Senseonics Holdings (SENS) is expanding its distribution network for implantable glucose monitors through pharmacies, ensuring high margins and supply stability. The market valuation trend for the asset is 14.24. The company develops unique Eversense subcutaneous sensors with a six-month lifespan, eliminating the need for diabetics to change devices frequently. Regular updates of the implanted sensors ensure a steady influx of operating capital and long-term business viability.

This indicator represents the average value of target prices based on discounted cash flow models, allowing for an assessment of the stock's mathematical growth potential relative to its current price. By analyzing the market consensus on the price of Senseonics Holdings (SENS), an investor can compare the calculated upside with the uniqueness of the Eversense six-month sensors, which determine the company's market share in the medtech sector.